Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevelamer Carbonate in Obesity-Related Glomerulopathy
NCT02644486Terminated
- Start
- Jan 2016
- Primary completion
- Feb 2018
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of sevelamer carbonate in obesity-related glomerulopathy (ORG) (3 arms). Primary endpoint: Low-Density Lipoprotein at 12 weeks. Started Jan 2016; status: terminated.
02
Drugs
sevelamer carbonate
03
Conditions
obesity-related glomerulopathy (ORG)
Beyond the preview
Go deeper on NCT02644486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02644486.